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The antiepileptic drug vigabatrin has shown efficacy in the treatment of patients with refractory epilepsy. Unlike 
many other antiepileptics it is not bound to plasma protein and mainly eliminated by the kidney. Although the 
therapeutic and toxic serum concentration range is not clearly defined and efficacy and toxicity are not closely 
correlated with the dose, factors decreasing vigabatrin elimination such as advanced age or renal failure may pose 
risk of untoward effects. Thus far there are no dose recommendations available for patients on haemodialysis. We 
report on an epileptic patient who experienced severe, partially reversible renal failure as a consequence of 
near-drowning. In this patient serum concentrations of vigabatrin were measured repeatedly both during 
haemodialysis and after partial recovery of renal function. The terminal elimination half-life in this patient was 41 
hours during the period of severe renal failure (creatinine clearance C5 ml/min). As about 60% of vigabatrin was 
removed from the blood pool by haemodialysis in these patients the antiepileptic should be administered after 
dialysis. To maintain serum concentrations in the usual range and to control seizure activity only 500 mg vigabatrin 
every 3 days were necessary. 
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INTRODUCTION 
As the principal inhibitory neurotransmitter in 
the human brain, GABA is believed to play a 
major role in controlling seizure activity’. Viga- 
batrin is a new ‘antiepileptic drug chemically 
related to gamma-aminobutyric acid (GABA)’ 
which irreversibly inhibits inactivation of GABA 
by GABA-transaminase and thereby leads to 
accumulation of the transmitte?2.3. Oral treatment 
with vigabatrin produces dose-dependent in- 
creases in cerebrospinal fluid levels of GABA in 
manly4 and substantial decreases in seizure 
frequency in patients with refractory epilepsy’95*6. 
Possibly due to its mechanism of irreversible 
enzyme inhibition, no clear correlation between 
serum concentrations and clinical effects has been 
observed’*5. In patients successfully treated with 
the drug, serum concentrations between 8 and 
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278 pmol/l have been reported’>. Hence serum 
concentration monitoring is considered to be of 
very limited value in the treatment of patients 
with the compound. It may, however, be helpful, 
e.g. to distinguish non-responding from non- 
compliant patients. 
Vigabatrin is supplied as a racemic mixture, 
with the S( +)-enantiomer possessing phar- 
macological activity and the R( -)-enantiomer 
being inactive*“. After oral administration (R, S)- 
vigabatrin is rapidly absorbed reaching peak 
serum concentrations within 2 hours after 
dosine’. Vigabatrin is not bound to plasma 
protein’. The apparent volume of distribution of 
(R, S)-vigabatrin is approximately 0.8 l/kg’. Vig- 
abatrin exhibits linear pharmacokinetics with a 
half-life between 5.3 and 7.4 hours’*‘. The major 
route of elimination is renal excretion of the 
unchanged compound’. The pharmacokinetic 
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changes observed in elderly volunteers, attributed 
to the well known decrease in renal function with 
age, imply that dose reductions in elderly patients 
and in those with renal insufficiency are required 
to prevent toxicity”. 
Thus far only limited information about the 
pharmacokinetics of vigabatrin in end-stage renal 
disease and during haemodialysis is published” 
and no dose recommendations for patients with 
severe renal failure are available. We report on a 
patient in whom serum concentrations of vigabat- 
tin were repeatedly measured at different levels 
of renal function as well as during haemodialysis 
and who required much lower maintenance doses 
than generally recommended for seizure control. 
CASE REPORT 
A 59-year-old male Caucasian who suffered from 
temporal lobe epilepsy with secondary general- 
ized seizures since his childhood experienced an 
epileptic fit while he was walking along a river 
and fell into the river. He was rescued by two 
people witnessing the accident, successfully re- 
suscitated, and admitted to the intensive care unit 
of our hospital. Because of respiratory 
insufficiency he was intubated and mechanically 
ventilated. During his 13-week stay on the 
intensive cae unit he encountered multiple 
complications such as granulocytopenic fever, 
toxic alveolar oedema, pneumonia with 
Pseudomonas aeruginosa, and liver insufficiency 
(ASAT 118U/l [normal: ~361, ALAT 83 U/l 
[normal: ~371, bilirubin 110 pmol/l [normal: 
~261). Within the first weeks he also developed 
acute anuric renal insufficiency (serum creatinine 
1127 pmol/l [normal: ~1171, creatinine clearance 
5 ml/minute as measured by determination of 
serum creatinine and 24-hour urine excretion of 
creatinine) due to hypoxic renal damage requir- 
ing haemodialysis during a period of 10 weeks. 
At the time of the accident he was maintained 
on a combination of four anticonvulsant drugs 
(lamotrigine, valproic acid, carbamazepine, clon- 
azepam). Because of progression of liver 
insufficiency (ASAT 268 U/l, ALAT 284 U/l, 
gamma-GT 996U/l [normal: ~661, alkaline 
phosphatase 521 U/l [normal: ~1081, bilrubin 
327 pmol/l) and the potential risk of bone 
marrow depression all antiepileptic drugs were 
discontinued and he was only maintained on 
midazolam which was primarily used as a sedative 
during mechanical ventilation. Throughout the 
period of mechanical ventilation seizures were 
absent, however, during the weaning phase from 
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Fig. 1: Vigabatrin serum concentration-time curve in a 
59-year-old patient with severe renal failure. Two 4-hour 
haemodialysis sessions are indicated with D. The solid lines 
represent linear regression curves of the terminal 
elimination phase during different states of renal failure 
which were used to calculate the respective half-lives. 
the respirator when midazolam was discontinued 
complex partial seizures became prominent 
again. For that reason antiepileptic treatment 
with vigabatrin was started. 
As vigabatrin pharmacokinetics are not well 
characterized under the condition of haemodialy- 
sis, serum concentrations of (R, S)-vigabatrin 
were monitored during the first days of treatment 
before, during and after haemodialysis (Fig. 1). 
Vigabatrin concentrations were determined by 
high-performance liquid chromatography using 
fluorescence detection as previously described’*. 
The limit of accurate detection was 1.5 pmol/l, 
the day-to-day coefficient of variation was 6.4% 
(n = 37, 43 pmol/l). Three doses of vigabatrin 
(500 mg) were administered orally at daily inter- 
vals. During these initial days the patient 
underwent haemodialysis twice. Serum vigabatrin 
concentrations immediately before and at the end 
of the 4-hour dialysis were 49 and 20 pmolll after 
the first and 64 and 26 pmol/l after the second 
dialysis, respectively, indicating that approxim- 
ately 60% of the serum pool were eliminated. 
After each dialysis serum concentrations in- 
creased suggesting the presence of a deep 
compartment and redistribution of vigabatrin 
during the hours following dialysis (Fig. 1). The 
half-life calculated from the elimination phase 
after the second haemodialysis was 41 hours. 
Hence, to maintain serum vigabatrin concentra- 
tions in a range between 20 and 100 pmol/l it was 
enough to administer 500 mg vigabatrin every 
three days. 
During the following weeks renal function 
gradually recovered to creatinine clearance 
values of 19 ml/minute at discharge of the 
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Fig. 2: Linear regression between vigabatrin elimination 
rate constant (In 2/serum half-life) and renal function in 
patients with mild to moderate renal insufficiency (extracted 
from Haegele et al. 1989; 0) and in our patient with severe 
renal failure (0). 
patient. The calculated vigabatrin half-life during 
that period was 24 hours (Fig. 1). Elimination rate 
constants calculated from the two elimination 
phases in our patient as well as from published 
figures for patients with moderate renal 
impairment” were linearly related to renal 
function (creatinine clearance) and are shown in 
Fig. 2. 
Seizure activity: before administration of viga- 
batrin the patient had complex partial seizures 
once to twice a week with occasional secondary 
generalization. No epileptic fits were noted after 
discontinuation of midazolam within the first 30 
days after onset of vigabatrin as long as serum 
concentrations were above 30 pmol/l. Two epis- 
odes of seizures were noted when renal function 
had improved (creatinine clearance 19 ml/min) 
both occurring on day 3 after dosing. For that 
reason the dosing interval was reduced to 500 mg 
every 2 days and the patient remained without 
seizures until discharge from the hospital 5 days 
later. 
DISCUSSION 
The central role of the kidney in the elimination 
of vigabatrin is well known and renal impairment 
has been incriminated for prolongations of the 
terminal half-life of the drug”. Thus far there are 
no dose recommendations and only limited 
information available about the pharmacokinetics 
of vigabatrin in end-stage renal disease”. The 
results in this patient on haemodialysis indicate 
that the terminal half-life of the drug may reach 
41 hours, which is approximately 6 times longer 
than values observed in healthy volunteers’*9*‘3. 
In this patient the elimination rate constants 
determined on two occasions were in good 
agreement with data extrapolated from the 
literature from patients with milder degrees of 
renal insufficiency. Compilation of the published 
figures with data of our patient with severe renal 
failure revealed the expected linear relationship 
between the vigabatrin elimination rate constant 
(ln2/half-life) and renal impairment. It is there- 
fore likely that the prolongation of vigabatrin 
elimination is mainly due to changes in renal drug 
clearance and not the result of alterations in drug 
distribution. Due to the markedly protracted 
elimination in this patient vigabatrin at a dose of 
500mg every 3 days was sufficient to sustain 
serum concentrations in the usually observed 
range. As there is no close relationship between 
serum concentrations and antiepileptic effect is is 
important to emphasize that the dosing regimen 
in this patient was also successfully maintaining 
antiepileptic efficacy. 
As expected for a small molecule not bound to 
proteins with a volume of distribution which is 
not excessively large, vigabatrin was substantially 
eliminated by a 4-hour haemodialysis. The 
amounts of drug removed in our patient are in 
accordance with data observed in another patient 
on dialysis . l1 It is noteworthy that during haemo- 
dialysis the removal of large vigabatrin amounts 
from the body was not associated with the 
recurrence of epileptic fits. This may be explained 
by its mechanism of irreversible enzyme inhibi- 
tion which is not acutely reversed by rapid 
withdrawal of the drug. Haemodialysis appears 
therefore safe even in patients on monotherapy 
with vigabatrin. However, as a substantial frac- 
tion of the blood is cleared within a single 
haemodialysis in these patients vigabatrin should 
preferentially be administered after dialysis. 
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